This report contains market size and forecasts of Bio Similars/Subsequent Entry Biologic in Global, including the following market information:
Global Bio Similars/Subsequent Entry Biologic Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Bio Similars/Subsequent Entry Biologic market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Monoclonal Antibodies Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Bio Similars/Subsequent Entry Biologic include Sun Pharma, Synthon Pharmaceuticals, Teva Pharmaceutical Industries, LG Life Sciences, Celltrion Biocon, Hospira, Merck, Biogen idec and Genentech (Roche), etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Bio Similars/Subsequent Entry Biologic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bio Similars/Subsequent Entry Biologic Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Bio Similars/Subsequent Entry Biologic Market Segment Percentages, by Type, 2021 (%)
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Global Bio Similars/Subsequent Entry Biologic Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Bio Similars/Subsequent Entry Biologic Market Segment Percentages, by Application, 2021 (%)
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
Global Bio Similars/Subsequent Entry Biologic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Bio Similars/Subsequent Entry Biologic Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Bio Similars/Subsequent Entry Biologic revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Bio Similars/Subsequent Entry Biologic revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sun Pharma
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion Biocon
Hospira
Merck
Biogen idec
Genentech (Roche)
Pfizer
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy's Laboratories
Stada Arzneimittel AG
AbbVie
Sanofi-Aventis
Johnson & Johnson
Novo Nordisk
Eli Lilly
Novartis
3sbio
Biotech
Gelgen
Innovent
Dong Bao
Ganlee